Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system
- 1 April 2021
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 897, 173961
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Review of direct renin inhibition by aliskirenJournal of the Renin-Angiotensin-Aldosterone System, 2013
- Angiotensin-Converting Enzyme 2: The First DecadeInternational Journal of Hypertension, 2011
- Sex Differences in Pharmacokinetics and PharmacodynamicsClinical Pharmacokinetics, 2009
- Estrogen Reduces Aldosterone, Upregulates Adrenal Angiotensin II AT2 Receptors and Normalizes Adrenomedullary Fra-2 in Ovariectomized RatsNeuroendocrinology, 2008
- Sex differences in circulating and renal angiotensins of hypertensive mRen().Lewis but not normotensive Lewis ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- X-inactivation profile reveals extensive variability in X-linked gene expression in femalesNature, 2005
- Differences Between Lovastatin and Simvastatin Hydrolysis in Healthy Male and Female Volunteers: Gut Hydrolysis of Lovastatin is Twice that of SimvastatinThe Scientific World Journal, 2003
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD)American Heart Journal, 1996
- The influence of reproductive hormones on ANF release by rat atriaLife Sciences, 1993